Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: A nested case-control approach

Stroke

Volumn 37, Issue 8, 2006, Pages 2007-2011

  Zee, Robert Y L ^a   Cheng, Suzanne ^b   Hegener, Hillary H ^a   Erlich, Henry A ^b   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

ALOX5AP; Haplotypes; MI; Risk factors; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BETA CAROTENE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; CARRIER PROTEIN; MEMBRANE PROTEIN;

ADULT; ALLELE; ARTICLE; ATHEROGENESIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EVALUATION; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; AGED; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; GENETIC PREDISPOSITION; GENETICS; ICELAND; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CARRIER PROTEINS; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; ICELAND; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; VARIATION (GENETICS);

EID: 33747183983     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000229905.25080.01     Document Type: Article

References (13)

1. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, Samani NJ, Gudmundsson G, Grant SF, Thorgeirsson G, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Johannsson H, Gudmundsdottir O, Gurney ME, Sainz J, Thorhallsdottir M, Andresdottir M, Frigge ML, Topol EJ, Kong A, Gudnason V, Hakonarson H, Gulcher JR, Stefansson K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233-239.
2. Helgadottir A, Gretarsdottir S, St Clair D, Manolescu A, Cheung J, Thorleifsson G, Pasdar A, Grant SF, Whalley LJ, Hakonarson H, Thorsteinsdottir U, Kong A, Gulcher J, Stefansson K, MacLeod MJ. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a scottish population. Am J Hum Genet. 2005;76:505-509.
3. Lohmussaar E, Gschwendtner A, Mueller JC, Org T, Wichmann E, Hamann G, Meitinger T, Dichgans M. AlOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke. 2005;36:731-736.
4. Meschia JF, Brott TG, Brown RD Jr, Crook R, Worrall BB, Kissela B, Brown WM, Rich SS, Case LD, Evans EW, Hague S, Singleton A, Hardy J. Phosphodiesterase 4d and 5-lipoxygenase activating protein in ischemic stroke. Ann Neurol. 2005;58:351-361.
5. Physician's health study. Aspirin and primary prevention of coronary heart disease. N Engl J Med. 1989;321:1825-1828.
6. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, Chen JJ, Pullinger CR, Malloy MJ, Siest G, Kane JP. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res. 1999;9:936-949.
7. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics. 1995;29:311-322.
8. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
9. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73:1162-1169.
10. Wallenstein S, Hodge SE, Weston A. Logistic regression model for analyzing extended haplotype data. Genet Epidemiol. 1998;15:173-181.
11. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220:568-575.
12. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Robenek H, Salbach P, Kuhn H, Radmark O, Samuelsson B, Habenicht AJ. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003;100:1238-1243.
13. Helgadottir A, Manolescu A, Helgason A, Thorleifsson G, Thorsteinsdottir U, Gudbjartsson DF, Gretarsdottir S, Magnusson KP, Gudmundsson G, Hicks A, Jonsson T, Grant SF, Sainz J, O'Brien SJ, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Levey AI, Abramson JL, Reilly MP, Vaccarino V, Wolfe ML, Gudnason V, Quyyumi AA, Topol EJ, Rader DJ, Thorgeirsson G, Gulcher JR, Hakonarson H, Kong A, Stefansson K. A variant of the gene encoding leukotriene a4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet. 2006;38:68-74.